TRIP announces that it has had its best week of sales ever, after consumers show confidence in superior quality CBD. TRIP (www.drink-trip.com) is the 4th fastest growing private company in the UK (Sunday Times 100) and the UK’s market leader in CBD products (with 88% market share of CBD drinks – Nielsen).
Holland & Barrett today reinstate all CBD products, after a temporary pause last week following the FSA announcement.
TRIP is distributed in 25,000 stores. While the FSA and Trading Standards confirmed publicly that there are no changes required to listings, product formulas, labelling or packaging; Holland & Barrett were the only retailer to temporarily put some TRIP beverage products on hold, this has now been lifted and all CBD products are available again.
TRIP are passionate about bringing the health benefits of CBD into the mainstream and destigmatising conversations around mental wellbeing, TRIP has always advocated for regulation of the industry and championed best in class compliance, supporting the FSA’s work for consumer food safety.
Last week, the FSA updated its recommended daily guideline of 10mg CBD, reduced from the previous 70mg limit. TRIP fully supports the FSA’s emphasis on food safety, while also highlighting that the guideline is based on the lowest grade of CBD assessed in a study of three CBD sources.
Independent third party studies conducted on TRIP’s source of CBD, reviewed by the FSA, generates a safety limit of 105mg (equivalent to seven cans per day), this demonstrates the materially different level of safety and purity in TRIP’s products.
Dr Julie Moltke, MD Medical CBD practitioner, researcher and published author said, “It is most surprising that when the majority of the high-quality CBD datasets that have been made public were assessed, the three datasets analysed by the FSA appeared to have a significantly lower daily guideline.
“It can be useful to compare to the daily guideline in other countries that have legalised CBD for many years – In Canada the daily upper guideline is for 200 mg/day and in the Netherlands it is 160 mg/day. It is also worth noting that in the UK the NHS upper prescription guideline for Epidiolex, a synthetic CBD given to children and adults with epilepsy, is 1750mg/day for a 70kg person”
The last week saw TRIP’s best week of sales to date, showing consumer confidence in superior quality CBD (TRIP Drink Ltd. Value Sales w/e 15.10.23 Nielsen Retail, Online & On-premise).
TRIP comment, “Following Mental Health Awareness Day (10th October) and after the FSA announcement TRIP had its best sales week ever with Britons continuing to choose TRIP CBD products to support their everyday wellbeing – having seen the benefits first hand over the past few years.”
TRIP is the CBD market leader with the top 7 best-selling CBD SKUs in the country over the last year (Source Nielsen Total Market Value Sales – 52 Weeks 03 June 23) and 88% of the CBD drinks market in the UK (Nielsen). The CBD in TRIP products wasn’t included in the FSA’s analysis, used as the basis of the announcement last week.
TRIP comment, “Not all CBD is created equal. The FSA updated recommended daily guideline of 10mg CBD dosage is based on a study of 3 lower grade ingredient samples, which does not include TRIP’s CBD.”
Dr Antonia Orsi, Director of Toxicology, PhD, MRpharmS, UKRT, ERT, MRQA, CSci has confirmed the following of the CBD in TRIP products:
“The CBD tested was considered to have a no observed adverse effect level at 150mg/kg body weight/day by an independent testing facility. This equates to a provisional acceptable daily intake of 105mg.”
Independent third party studies conducted on TRIP’s source of CBD reviewed by the FSA, generates a safety limit of 105mg (equivalent to seven cans per day). This demonstrates the materially different level of purity in TRIP’s products.